Seizure: European Journal of Epilepsy
Volume 19, Issue 7 , Pages 375-382, September 2010

Antiepileptic treatment in patients with epilepsy and other comorbidities

  • J. Ruiz-Giménez

      Affiliations

    • Unidad de Epilepsia, Servicio de Neurologia, Hospital Universitario Virgen de las Nieves, Granada, España
    • Corresponding Author InformationCorresponding author at: Hospital de Rehabilitación y Traumatologia, Servicio de Neurologia, Carretera de Jaen, s/n 18013, Granada, Spain. Tel.: +34 659091751; fax: +34 958021564.
  • ,
  • J.C. Sánchez-Álvarez

      Affiliations

    • Servicio de Neurologia, Hospital Clinico Universitario San Cecilio, Granada, España
  • ,
  • F. Cañadillas-Hidalgo

      Affiliations

    • Servicio de Neurología, Hospital Universitario Reina Sofia, Cordoba, España
  • ,
  • P.J. Serrano-Castro

      Affiliations

    • Unidad de Neurologia y Neurofisiología, Hospital Torrecardenas, Almeria, España
  • ,
  • on behalf of the Andalusian Epilepsy Society

Received 9 November 2009; received in revised form 18 April 2010; accepted 20 May 2010. published online 16 June 2010.

Abstract 

Background

A high number of patients with epilepsy have comorbidities. The type of comorbidity is an important factor in deciding on the most suitable treatment, including that for acute epileptic seizures and chronic antiepileptic treatment. Evidence-based criteria should guide the selection of the appropriate antiepileptic drugs given specific comorbidities.

Methods

We performed a comprehensive search of the scientific literature on epilepsy treatment in patients with the following comorbidities: heart disease, lung disease, liver disease, kidney disease, porphyria, organ transplantation, thyroid disease, metabolic disorder, infection, mental disability, psychiatric disorder, cognitive impairment, stroke, and brain tumour.

Results

Most of the studies were case series and retrospective analyses. No randomised controlled trials specifically designed for this type of clinical situation were identified. The level of scientific evidence to guide clinical decisions is therefore low.

Conclusions

In this review we make recommendations based on the best scientific evidence available for treating epilepsy in patients with other comorbidities, including the treatment of epileptic seizures in acute situations as well as chronic antiepileptic treatment. When no scientific evidence is available, our recommendations are based on pharmacokinetic criteria and tolerability of antiepileptic drugs, using accumulated experience and the consensus of the members of the Andalusian Epilepsy Society.

Keywords: Anticonvulsants, Comorbidity, Drug interactions, Epilepsy, Guidelines, Treatment

 

 This review has been extracted, modified and adapted from the Andalusian Guideline on Epilepsy 2009 (http://www.guiasade.com), written by: O. Alonso-Luengo, E. Bauzano-Poley, H. Busquier-Hernández, R. Camino-León, F. Cañadillas-Hidalgo, J. Galán-Barranco, F.J. Gascón-Jiménez, A. Galdón-Castillo, D. García-Solís, J. Gutiérrez-García, M. Ley-Martos, E. López-Laso, J. Martínez-Antón, C. Martínez-Parra, C. Martínez-Quesada, J. Mercadé-Cerdá, M.D. Morales-Martínez, V. Moreno-Alegre, M. Nieto-Barrera, E. Pita-Calandre, M.M. Quesada-Lucas, P.A. Quiroga-Subirana, J. Ramos-Lizana, C. Robles-Vizcaíno, J.J. Rodríguez-Uranga, S. Roldán-Aparicio, M. Rufo-Campos, J. Ruiz-Giménez, J.C. Sánchez-Álvarez, P.J. Serrano-Castro, F. Villalobos-Chaves.

PII: S1059-1311(10)00112-3

doi:10.1016/j.seizure.2010.05.008

Seizure: European Journal of Epilepsy
Volume 19, Issue 7 , Pages 375-382, September 2010